ANAB - AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.

52W High

$40.70

52W Low

$12.21

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

-0.18

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.30

EV/Revenue (<3 favorable)

2.94

P/S (TTM) (<3 favorable)

4.97

P/B (<3 favorable)

114.73

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

5.82%

Institutions (25–75% balanced)

124.29%

Shares Outstanding

27,973,000

Float

15,983,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

123,164,000

Gross Profit (TTM)

-40,641,000

EPS (TTM)

-4.39

Profit Margin (>10% good)

-1.08%

Operating Margin (TTM) (higher better)

-1.18%

ROE (TTM) (>15% strong)

-3.44%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.03

Momentum

Bearish momentum

Value

0.2959

0.1491

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025